McKesson (MCK) Q2 2024 Earnings
McKesson reported Q2 2024 revenue of $79.3B, missed analyst consensus of $82.5B by $3.2B. Diluted EPS came in at $7.88, beat the $7.21 consensus by $0.67. McKesson reports across 4 business segments, led by U.S. Pharmaceutical, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about McKesson's Q2 2024 earnings report.
McKesson (MCK) reported Q2 2024 earnings on August 7, 2024 after market close.
McKesson reported revenue of $79.3B and diluted EPS of $7.88 for Q2 2024.
Revenue missed the consensus estimate of $82.5B by $3.2B. EPS beat the consensus estimate of $7.21 by $0.67.
You can read the 10-Q periodic report (0000927653-24-000098) directly on SEC EDGAR. The filing index links above go to sec.gov.